Company Kane Biotech Inc Other OTC
Equities
CA4838091094
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-15 | Kane Biotech Expands Wound Care Portfolio with Patented Schultz Biofilm Wound Map | MT |
04-18 | Transcript : Kane Biotech Inc. - Special Call |
Business Summary
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
All Other
100.0
%
| 0 | 5.9 % | 0 | 100.0 % | -4.95% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
International
93.1
%
| 1 | 55.5 % | 0 | 93.1 % | -90.63% |
Canada
6.9
%
| 1 | 44.5 % | 0 | 6.9 % | -99.13% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Marc Edwards
CEO | Chief Executive Officer | - | 01/06/16 |
Ray Dupuis
DFI | Director of Finance/CFO | - | 04/09/17 |
Compliance Officer | - | 11/08/19 | |
Gregory Schultz
CTO | Chief Tech/Sci/R&D Officer | 73 | 04/04/22 |
John Coleman
BRD | Director/Board Member | - | 11-15 |
Wendy Nachtigall
SAM | Sales & Marketing | - | 30/09/15 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
R. Renaud
BRD | Director/Board Member | - | 14/09/10 |
Chairman | 59 | 02-19 | |
Georges Morin
BRD | Director/Board Member | - | 19/05/20 |
Marc Edwards
CEO | Chief Executive Officer | - | 01/06/16 |
John Coleman
BRD | Director/Board Member | - | 11-15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 131,844,567 | 85,786,381 ( 65.07 %) | 0 | 65.07 % |
Company contact information
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
+64.23% | 55.07B | |
-2.31% | 41.79B | |
+44.36% | 40.22B | |
-8.29% | 28.17B | |
+11.97% | 26.28B | |
-21.16% | 18.93B | |
+7.54% | 13.03B | |
+27.17% | 12.26B | |
+25.72% | 12.21B |
- Stock Market
- Equities
- KNE Stock
- Stock
- Company Kane Biotech Inc